Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Advanced Minimal Residual Disease Detection Using a Novel Circulating Tumor DNA Assay: A Report of Two Cases

Advanced Minimal Residual Disease Detection Using a Novel Circulating Tumor DNA Assay: A Report of Two Cases

Authors: Azzi G, Slavin T, Izaguirre-Carbonell J, Sloane HS, Edelstein DL, Ma CX

Citation: Case Rep Oncol. 2025 Jul 10. doi:10.1159/000547249. Online ahead of print.

Specialties: Oncology

Related content

Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Test FAQ
Haystack MRD Testing
Publication
NGS defined measurable residual disease MRD after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia
Publication
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.